199 related articles for article (PubMed ID: 15605208)
21. [Systemic sclerosis: different subsets and disease remitting drugs].
Ogawa T; Saito E
Nihon Rinsho; 1999 Feb; 57(2):344-8. PubMed ID: 10078002
[TBL] [Abstract][Full Text] [Related]
22. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
[TBL] [Abstract][Full Text] [Related]
23. [Modern perspective on the development conditions and diagnosis of systemic sclerosis].
Wielosz E
Wiad Lek; 2017; 70(4):855-859. PubMed ID: 29064817
[TBL] [Abstract][Full Text] [Related]
24. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
25. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
26. Current management strategies for systemic sclerosis.
Nihtyanova SI; Ong VH; Denton CP
Clin Exp Rheumatol; 2014; 32(2 Suppl 81):156-64. PubMed ID: 24742450
[TBL] [Abstract][Full Text] [Related]
27. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features.
Valentini G; Cuomo G; Abignano G; Petrillo A; Vettori S; Capasso A; Cozzolino D; Del Genio G; Santoriello C
Rheumatology (Oxford); 2011 Feb; 50(2):317-23. PubMed ID: 20562195
[TBL] [Abstract][Full Text] [Related]
28. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
29. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.
Castelino FV; Varga J
Expert Rev Clin Immunol; 2013 Nov; 9(11):1077-90. PubMed ID: 24168414
[TBL] [Abstract][Full Text] [Related]
30. [Plasmapheresis therapy in systemic sclerosis].
Szúcs G; Szamosi S; Aleksza M; Veres K; Soltész P
Orv Hetil; 2003 Nov; 144(45):2213-7. PubMed ID: 14686006
[TBL] [Abstract][Full Text] [Related]
31. Scleroderma therapy: clinical overview of current trends and future perspective.
Topal AA; Dhurat RS
Rheumatol Int; 2013 Jan; 33(1):1-18. PubMed ID: 23011088
[TBL] [Abstract][Full Text] [Related]
32. Systemic sclerosis: from pathogenesis to targeted therapy.
Denton CP
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S3-7. PubMed ID: 26457375
[TBL] [Abstract][Full Text] [Related]
33. Systemic sclerosis: a critical digest of the recent literature.
Barsotti S; Stagnaro C; Della Rossa A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S3-14. PubMed ID: 26243174
[TBL] [Abstract][Full Text] [Related]
34. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and serological diversity in systemic sclerosis].
Wielosz E; Majdan M
Wiad Lek; 2018; 71(1 pt 1):78-83. PubMed ID: 29558356
[TBL] [Abstract][Full Text] [Related]
36. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.
Affandi AJ; Radstake TR; Marut W
Semin Immunopathol; 2015 Sep; 37(5):475-87. PubMed ID: 26168983
[TBL] [Abstract][Full Text] [Related]
37. Severe organ involvement in systemic sclerosis with diffuse scleroderma.
Steen VD; Medsger TA
Arthritis Rheum; 2000 Nov; 43(11):2437-44. PubMed ID: 11083266
[TBL] [Abstract][Full Text] [Related]
38. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.
Kumar S; Singh J; Rattan S; DiMarino AJ; Cohen S; Jimenez SA
Aliment Pharmacol Ther; 2017 Apr; 45(7):883-898. PubMed ID: 28185291
[TBL] [Abstract][Full Text] [Related]
39. Scleroderma--clinical and pathological advances.
Denton CP; Black CM
Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
[TBL] [Abstract][Full Text] [Related]
40. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
Gordon JK; Domsic RT
Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
